159 related articles for article (PubMed ID: 28164492)
21. Prognostic value of plasma microRNAs for non-small cell lung cancer based on data mining models.
Yan M; Kang W; Liu X; Yang B; Sun N; Yang Y; Wang W
BMC Cancer; 2024 Jan; 24(1):52. PubMed ID: 38200421
[TBL] [Abstract][Full Text] [Related]
22. Micro RNA-148a Targets Bcl-2 in Patients with Non-Small Cell Lung Cancer.
Elnaggar GN; El-Hifnawi NM; Ismail A; Yahia M; Elshimy RAA
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1949-1955. PubMed ID: 34181356
[TBL] [Abstract][Full Text] [Related]
23. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer.
Wang Y; Gu J; Roth JA; Hildebrandt MA; Lippman SM; Ye Y; Minna JD; Wu X
Cancer Res; 2013 Aug; 73(15):4801-9. PubMed ID: 23774211
[TBL] [Abstract][Full Text] [Related]
24. A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material.
Bediaga NG; Davies MP; Acha-Sagredo A; Hyde R; Raji OY; Page R; Walshaw M; Gosney J; Alfirevic A; Field JK; Liloglou T
Br J Cancer; 2013 Oct; 109(9):2404-11. PubMed ID: 24113142
[TBL] [Abstract][Full Text] [Related]
25. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.
Porzycki P; Ciszkowicz E; Semik M; Tyrka M
Int Urol Nephrol; 2018 Sep; 50(9):1619-1626. PubMed ID: 30014459
[TBL] [Abstract][Full Text] [Related]
26. Profiling of 179 miRNA Expression in Blood Plasma of Lung Cancer Patients and Cancer-Free Individuals.
Zaporozhchenko IA; Morozkin ES; Ponomaryova AA; Rykova EY; Cherdyntseva NV; Zheravin AA; Pashkovskaya OA; Pokushalov EA; Vlassov VV; Laktionov PP
Sci Rep; 2018 Apr; 8(1):6348. PubMed ID: 29679068
[TBL] [Abstract][Full Text] [Related]
27. A Highly Efficient Gene Expression Programming (GEP) Model for Auxiliary Diagnosis of Small Cell Lung Cancer.
Yu Z; Lu H; Si H; Liu S; Li X; Gao C; Cui L; Li C; Yang X; Yao X
PLoS One; 2015; 10(5):e0125517. PubMed ID: 25996920
[TBL] [Abstract][Full Text] [Related]
28. Whole Blood-Derived circUSP10 Acts as a Diagnostic Biomarker in Patients With Early-Stage Non-Small-Cell Lung Cancer.
Bai H; Jiang M; Fang S; Peng Z; Liang N; Cai Y; Wang Y; Zhou C; Han Y; Shen W; Gong Z
Cell Transplant; 2023; 32():9636897231193066. PubMed ID: 37632352
[TBL] [Abstract][Full Text] [Related]
29. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer.
Bianchi F; Nicassio F; Marzi M; Belloni E; Dall'olio V; Bernard L; Pelosi G; Maisonneuve P; Veronesi G; Di Fiore PP
EMBO Mol Med; 2011 Aug; 3(8):495-503. PubMed ID: 21744498
[TBL] [Abstract][Full Text] [Related]
30. Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung cancer.
Xiong L; Zhu C; Lu Y; Chen M; Li M
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15671-15677. PubMed ID: 37658862
[TBL] [Abstract][Full Text] [Related]
31. Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum.
Cai S; Pataillot-Meakin T; Shibakawa A; Ren R; Bevan CL; Ladame S; Ivanov AP; Edel JB
Nat Commun; 2021 Jun; 12(1):3515. PubMed ID: 34112774
[TBL] [Abstract][Full Text] [Related]
32. Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice.
Taverna S; Giallombardo M; Gil-Bazo I; Carreca AP; Castiglia M; Chacártegui J; Araujo A; Alessandro R; Pauwels P; Peeters M; Rolfo C
Oncotarget; 2016 May; 7(19):28748-60. PubMed ID: 26919248
[TBL] [Abstract][Full Text] [Related]
33. Screening of lung cancer serum biomarkers based on Boruta-shap and RFC-RFECV algorithms.
Yue G
J Proteomics; 2024 Jun; 301():105180. PubMed ID: 38663548
[TBL] [Abstract][Full Text] [Related]
34. Urinary N1, N12-diacetylspermine is a non-invasive marker for the diagnosis and prognosis of non-small-cell lung cancer.
Takahashi Y; Sakaguchi K; Horio H; Hiramatsu K; Moriya S; Takahashi K; Kawakita M
Br J Cancer; 2015 Nov; 113(10):1493-501. PubMed ID: 26505680
[TBL] [Abstract][Full Text] [Related]
35. Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer.
Moretti F; D'Antona P; Finardi E; Barbetta M; Dominioni L; Poli A; Gini E; Noonan DM; Imperatori A; Rotolo N; Cattoni M; Campomenosi P
Oncotarget; 2017 Nov; 8(55):94980-94996. PubMed ID: 29212284
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of blood biomarkers in elderly patients with non-small-cell lung cancer.
Guo L; Song B; Xiao J; Lin H; Chen J; Jian B
Biomark Med; 2023 Dec; 17(24):1011-1019. PubMed ID: 38235564
[No Abstract] [Full Text] [Related]
37. A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis.
Umu SU; Langseth H; Keller A; Meese E; Helland Å; Lyle R; Rounge TB
Mol Oncol; 2020 Feb; 14(2):235-247. PubMed ID: 31851411
[TBL] [Abstract][Full Text] [Related]
38. Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis.
Mohamed E; García Martínez DJ; Hosseini MS; Yoong SQ; Fletcher D; Hart S; Guinn BA
Carcinogenesis; 2024 Feb; 45(1-2):1-22. PubMed ID: 38066655
[TBL] [Abstract][Full Text] [Related]
39. Circulating exosomal miRNAs as a promising diagnostic biomarker in cancer.
Lohajová Behulová R; Bugalová A; Bugala J; Struhárňanská E; Šafranek M; Juráš I
Physiol Res; 2023 Oct; 72(S3):S193-S207. PubMed ID: 37888964
[TBL] [Abstract][Full Text] [Related]
40. CircBRIP1: a plasma diagnostic marker for non-small-cell lung cancer.
Fan X; Zhang Q; Qin S; Ju S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):83. PubMed ID: 38329551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
